Sign in
HMTXF Stock Price, Chart, Stats & News
Hemostemix Inc
Save
Hemostemix Inc (HMTXF) does not currently pay a dividend.
8.67M
Market cap
–
Current P/E
–
Forward P/E
HMTXF chart
1M
3M
1Y
5Y
Loading chart...
About
Health care
Sector
Biotechnology
Industry
Hemostemix, Inc. is a clinical-stage biotechnology company, which is focused on developing and commercializing a proprietary autologous cell therapy to treat ischemic diseases. The firm's, ACP-01, lead clinical stage candidate, is an autologous cell therapy for the treatment of critical limb ischemia. The company was founded by Roger Bergersen and Thomas A.
Similar securities
Based on sector and market capitalization
Report issue